Home

Articles from AKAMPION

BellaSeno Successfully Completes Two Clinical Trials with Novel, Resorbable Breast Implants
Leipzig, Germany/ Brisbane, Australia, January 14, 2025 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that all 19 breast scaffold patients enrolled in 2022 in an Australian breast augmentation revision trial have successfully completed a one-year follow-up without any major scaffold-related complications or scaffold removals. In addition, in a parallel Australian clinical trial, 7 pectus excavatum patients have successfully passed one-year follow-up. The trials are the first-ever implant trials using a novel approach combining polycaprolactone (PCL) scaffolds, ultimately resulting in a fully resorbed implant and natural tissue. The data show that it is possible to replace silicone implants in breast augmentation with alternatives offering improved safety and quality of life.
By AKAMPION · Via GlobeNewswire · January 14, 2025
tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat
- tiakis and Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH)
By AKAMPION · Via GlobeNewswire · January 8, 2025
Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark
Denmark – Odense – 07/01/2025 – Inverna Therapeutics, a novel Danish biotech company at the forefront of innovative RNA therapeutics, today announced its launch as a leading-edge RNA therapeutics company.  The Company was co-founded by the University of Southern Denmark and Argobio and is dedicated to transforming patient outcomes in severe genetic diseases, starting with a lead program addressing Huntington’s disease.
By AKAMPION · Via GlobeNewswire · January 7, 2025
tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients
-       Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy
By AKAMPION · Via GlobeNewswire · December 9, 2024
Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001
Munich, Germany – December 4, 2024 – Thermosome, a drug development company focused on targeted tumor therapies, today announced its ongoing Phase I trial has progressed to dose level 3 (DL3) after the independent Data Safety Monitoring Board (DSMB) declared dose level 2 (DL2) as safe and recommended escalation to the final dose level (DL3). In the trial, the Company’s lead compound THE001 is tested in patients with heavily pre-treated, locally advanced unresectable or metastatic soft tissue sarcoma (STS) in combination with regional hyperthermia. To date, the safety profile remains favorable with no dose-limiting toxicities and no suspected unexpected serious adverse event (SUSAR) seen at DL1 and DL2, respectively. Most adverse events were low-grade (CTCAE ≤ grade 2), reversable, and were to be expected for the active pharmaceutical ingredient doxorubicin.
By AKAMPION · Via GlobeNewswire · December 4, 2024
Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001
Munich, Germany – November 19, 2024 – Thermosome, a drug development company focused on targeted tumor therapies, today announced encouraging initial clinical data from the ongoing Phase I study of its lead compound THE001 in patients with heavily pre-treated, locally advanced unresectable or metastatic soft tissue sarcoma (STS). The data were presented as a poster (#P410) titled “Phase I study of THE001 (DPPG2-TSL-DOX) combined with regional hyperthermia in patients with locally advanced or metastatic soft tissue sarcoma” at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024 in San Diego, USA.
By AKAMPION · Via GlobeNewswire · November 19, 2024
Ebenbuild Appoints Charles A. Taylor, PhD as Chairman of the Board
Munich, Germany, November 11, 2024 -- Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced that Charles A. Taylor, PhD has been appointed Chairman of the Board. Dr. Taylor is a pioneer in the field of predictive, simulation-based medicine where he applied computational fluid dynamics to predict outcomes of cardiovascular interventions in individual patients.
By AKAMPION · Via GlobeNewswire · November 11, 2024
AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study
Basel (Switzerland), October 23, 2024 – AMYRA Biotech AG (“AMYRA”), a company developing novel, oral digestive enzyme therapeutics for gastrointestinal diseases announced the peer-reviewed publication of its clinical proof-of-principle study with its lead product AMYNOPEP in Frontiers in Immunology - Nutritional Immunology (https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1425982/full). AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical endogenous enzymes on the lining of the small intestine. AMYNOPEP is designed to break down hard-to-digest gluten peptides into harmless and absorbable single amino acids and dipeptides, thereby supporting individuals with gluten-related health disorders in avoiding exposure to inflammatory peptides. AMYRA’s first-in-human clinical study assessed gluten-digesting enzyme efficacy using high-resolution analytics and demonstrated in near-real-time that AMYNOPEP swiftly and significantly enhanced the digestion of proteolytically-resistant, immunogenic gluten peptides in healthy volunteers.
By AKAMPION · Via GlobeNewswire · October 23, 2024
Preliminary Data of BellaSeno’s Clinical Trial on Scaffold-Guided Breast Regeneration Presented at the 93rd Annual Plastic Surgery Meeting in San Diego, CA
Leipzig, Germany, October 9, 2024 - BellaSeno GmbH, an ISO 13485 certified tissue regeneration company developing resorbable scaffolds using additive manufacturing technologies, today announced that new clinical data from the first interim report of its ongoing study evaluating the use of BellaSeno's 3D-printed resorbable breast scaffolds (ClinicalTrials.gov ID NCT05437757) were presented at the 93rd Annual Plastic Surgery Meeting in San Diego, CA, USA (Sept. 26 - 29, 2024).
By AKAMPION · Via GlobeNewswire · October 9, 2024
Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs
Schlieren, Zurich/Switzerland, September 24, 2024 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association.
By AKAMPION · Via GlobeNewswire · September 24, 2024
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
September 17, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a Series C financing round of $11 million. The round was led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures as well as other existing investors. In conjunction with the round, Steve Tregay, PhD, Managing General Partner of Mission BioCapital, has joined the Company’s Board of Directors.
By AKAMPION · Via GlobeNewswire · September 17, 2024
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
Schlieren (Zurich Area), Switzerland – July 24, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company using its HLA-based technology platform to develop first-in-class and innovative therapeutics for the treatment of cancer and autoimmune diseases, today announced the expansion of its ongoing  Phase I clinical trial of IOS-1002 in combination with MSD (Merck & Co., Inc., Rahway, NJ, USA)'s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of advanced solid tumors.
By AKAMPION · Via GlobeNewswire · July 24, 2024
BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients
Leipzig, Germany/ Brisbane, Australia, June 12, 2024 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that 10 breast scaffold patients and 5 pectus patients have successfully passed one-year follow-up in BellaSeno´s Australian clinical trials.
By AKAMPION · Via GlobeNewswire · June 12, 2024
Thermosome Appoints Dr. Sabine Hauck as Chief Technical Officer
-    Experienced biopharma professional focused on drug product development
By AKAMPION · Via GlobeNewswire · June 11, 2024
BellaSeno Receives Financial Support Through Queensland’s Industry Partnership Program
Leipzig, Germany, and Queensland, Australia. June 5, 2024 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced today that its Australian subsidiary has received financial assistance through the Queensland Government’s Industry Partnership Program.
By AKAMPION · Via GlobeNewswire · June 5, 2024
selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis
- New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity
By AKAMPION · Via GlobeNewswire · May 28, 2024
Captain T Cell Secures Seed Financing Round Totaling € 8.5 Million
Schoenefeld/Berlin, Germany, May 22, 2024 --- Captain T Cell GmbH, a biotechnology company developing next-generation T cells against solid tumors, today announced the successful closing of a seed financing round totaling € 8.5 million. A syndicate of experienced life science investors including i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H participated in the round. In addition, the German Federal Ministry of Education and Research (BMBF) is supporting the Company through its prestigious GO-Bio program. The financing also marks the appointment of biotech veteran Jörn Aldag as Chairman of the Board of Directors.
By AKAMPION · Via GlobeNewswire · May 22, 2024
Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update
Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief Executive Officer (CEO). Formerly known as HpVac, the Company has repositioned itself under the new name Atopia Therapeutics to better reflect its commitment to addressing the growing global burden of atopic diseases.
By AKAMPION · Via GlobeNewswire · May 7, 2024
selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis
San Diego, CA, USA, and Munich, Germany – April 29, 2024 - selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments for T-cell mediated autoimmune diseases, today announced positive results from the first-in-human Phase 1b trial of its lead compound, si-544, in atopic dermatitis patients. si-544 is a selectivity-optimized peptide blocking the ion channel Kv1.3.
By AKAMPION · Via GlobeNewswire · April 29, 2024
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track Record
Bad Homburg v.d. Höhe, Germany, April 23, 2024 - ForTra gGmbH für Forschungstransfer der Else Kröner-Fresenius-Stiftung (ForTra gGmbH), a non-profit arm of Else Kröner-Fresenius Foundation, today published the successful track record of its latest funding projects. Since 2017, the organization has been supporting basic biomedical research projects in their efforts to accelerate their transfer into clinical practice. From 2017 to the end of September 2023, 31 projects were funded, of which 16 were able to secure follow-on financing from public funds, venture capitalists or similar organizations. More than a third (11) of the completed projects have already entered clinical development. One of the first funded projects, which is developing a new strategy for cancer therapy, led to the founding of a start-up company in 2020 and has succeeded in bringing their drug candidate into the final phase of clinical development (Phase III).
By AKAMPION · Via GlobeNewswire · April 23, 2024
BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs
Leipzig, Germany, April 3, 2024 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced today that Dr. Thomas Lingner was appointed Chief Technology Officer and Inga Freyert was promoted to VP Quality and Regulatory Affairs.
By AKAMPION · Via GlobeNewswire · April 3, 2024
MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts
Zurich, March 13, 2024 – MetrioPharm AG, a clinical stage biotech company developing drugs for inflammatory and infectious diseases, today announced that it has established a Scientific Advisory Board (SAB). The newly appointed members are:
By AKAMPION · Via GlobeNewswire · March 13, 2024
BellaSeno’s 3D-printed Resorbable Scaffold Successfully Used in Critical-Size Large Segmental Radius Bone Defect at Hannover Medical School
-- Trauma patient suffered from third degree open infected fracture of its radial shaft after injury by a bullet
By AKAMPION · Via GlobeNewswire · March 5, 2024
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
- Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria
By AKAMPION · Via GlobeNewswire · February 20, 2024
Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001
-    First dose level rated as safe by independent Data Safety Monitoring Board-    Second dose level to be administered according to plan-    THE001 designed as targeted tumor treatment independent of specific molecular targets or tumor subtypes
By AKAMPION · Via GlobeNewswire · February 6, 2024
MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
Zurich, January 31, 2024 – MetrioPharm AG, a biotech company developing drugs for inflammatory and infectious diseases, announced today that results from its clinical trial CT-05 in hospitalized patients with moderate to severe COVID-19 have been published in the renowned journal The Lancet Regional Health – Europe.
By AKAMPION · Via GlobeNewswire · January 31, 2024
New investigator-initiated clinical trials of BellaSeno´s resorbable tissue regeneration scaffolds to be conducted in Europe
Leipzig, Germany, January 31, 2024 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that additional, investigator-initiated clinical trials of its novel regenerative scaffolds for bone reconstruction and chest-wall defects (pectus excavatum) will be conducted in Germany and Italy, respectively. In 2023, BellaSeno had received market authorization for its custom-made, resorbable bone and pectus excavatum scaffolds in Europe.
By AKAMPION · Via GlobeNewswire · January 31, 2024
selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024
San Diego, CA, USA, and Munich, Germany – January 5, 2024 - selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments for T cell mediated autoimmune diseases, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation will be held Thursday, January 11, 2024, 08:00 AM - 08:25 AM PST at Golden Gate (32nd Floor), The Westin.
By AKAMPION · Via GlobeNewswire · January 5, 2024
1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors
YONGIN, South Korea, December 14, 2023 – 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative diseases, immuno-oncology, and rare diseases, today announced the first patient dosing in the clinical Phase I/II trial evaluating FB849 in patients with advanced solid tumors.
By AKAMPION · Via GlobeNewswire · December 14, 2023
ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023
Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA  – December 11, 2023 – ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.
By AKAMPION · Via GlobeNewswire · December 11, 2023
Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board
-    Two renowned oncology experts to support the development of Thermosome's clinical candidate THE001
By AKAMPION · Via GlobeNewswire · December 5, 2023
EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001
Munich, Germany, December 4, 2023 – EBViously, a start-up developing novel vaccines based on next-generation virus-like particles, has presented new in vitro data of its EBV-vaccine candidate EBV-001 at the World Vaccine Congress West Coast 2023 (Nov. 27-30, 2023) in Santa Clara, CA (USA). The presentation by EBViously’s designated COO Sebastian Goy was held on Thursday, November 30, 2023.
By AKAMPION · Via GlobeNewswire · December 4, 2023
Ebenbuild to Receive Public Funding Under UBIC Consortium for Digital Lung Twin Project
Munich, Germany, November 28, 2023 -- Ebenbuild, a company developing personalized, AI-driven virtual lungs to support clinical decisions and digital clinical trials, today announced its participation in the research project Personalized Lung Twins for the Treatment of Acute Respiratory Distress Syndrome (UBIC) in collaboration with the University Hospital Schleswig-Holstein, Augsburg University Hospital, University Hospital Carl Gustav Carus Dresden, University Hospital RWTH Aachen and University Medical Center Mannheim.
By AKAMPION · Via GlobeNewswire · November 28, 2023
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
- Phase I data show safety and tolerability at clinically significant dose levels- New class of anti-infectives to treat infections with Gram-negative bacteria
By AKAMPION · Via GlobeNewswire · November 20, 2023
Dr. Hartmut Tintrup joins Cellbox Solutions GmbH as new CEO
- Seasoned business development professional joins from Lonza
By AKAMPION · Via GlobeNewswire · November 1, 2023
BellaSeno Presents Novel Production Workflow for Customized, 3D-Printed Bone Scaffolds
Leipzig, Germany, October 30, 2023 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that the Company has presented novel data on the design and manufacturing of customized, 3D-printed bone scaffolds at the recent German Congress of Orthopaedics and Traumatology (DKOU).
By AKAMPION · Via GlobeNewswire · October 30, 2023
ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA  – October 24, 2023 – ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, today announced an update on the ongoing Phase 1a/b trial of its lead program IOS-1002 in Australia. The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.
By AKAMPION · Via GlobeNewswire · October 24, 2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors  
By AKAMPION · Via GlobeNewswire · October 17, 2023
Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial
- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression- First data readout expected in Q1/ 2024 with study completion planned for September 2024
By AKAMPION · Via GlobeNewswire · September 26, 2023
Cellbox Solutions Submits Device Master File (DMF) to the U.S. FDA
Hamburg, Germany, September 25, 2023 – Cellbox Solutions GmbH, a leading provider of warm chain logistics solutions for the research, development and shipment of cell-based therapies and cellular diagnostics, today announced that is has successfully submitted a Device Master File (DMF) for its Cellbox Live Shipment Technology  to the U.S. Food and Drug Administration’s (FDA). The DMF is a detailed dossier submitted to the FDA which contains confidential and proprietary information regarding specifications of the Cellbox technology.
By AKAMPION · Via GlobeNewswire · September 25, 2023
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA® (pembrolizumab)
YONGIN, South Korea, September 19, 2023 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative diseases, immuno-oncology, and rare diseases, today announced a Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to evaluate FB849 in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a Phase I/II clinical trial for the treatment of patients with advanced solid tumors.
By AKAMPION · Via GlobeNewswire · September 19, 2023
Thermosome Establishes High-Profile Clinical Advisory Board
Munich, Germany – September 19, 2023 – Thermosome, a drug development company specializing in targeted tumor therapies, today announced the formation of a Clinical Advisory Board to support the advancement of its lead compound THE001 through clinical development.
By AKAMPION · Via GlobeNewswire · September 19, 2023
ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development
- Former Novartis Executive Director brings significant expertise in manufacturing, operations, and technical development
By AKAMPION · Via GlobeNewswire · September 19, 2023
BellaSeno Reports Positive One-Year Patient Follow-Up Data for Resorbable Breast and Pectus Excavatum Scaffolds
Leipzig, Germany, September 5, 2023 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today reported encouraging one-year follow-up data of its breast and pectus excavatum scaffolds.
By AKAMPION · Via GlobeNewswire · September 5, 2023
TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing
Heidelberg, July 6, 2023 – TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, today announced that in the TOL2- Phase IIb study in renal transplant patients TolerogenixX has received green light by the Safety Board to initiate the B arm of the study. This arm consists of patients receiving minimal immune suppression drugs, reducing tacrolimus and weaning off enteric-coated mycophenolate sodium and methylprednisolone completely. The study enrolls 63 transplant couples consisting of a donor and a transplant recipient, respectively. The protocol has been published in BMJ Open.
By AKAMPION · Via GlobeNewswire · July 6, 2023
BellaSeno Granted Market Access in Europe for Custom-Made Bone and Pectus Excavatum Scaffolds
Leipzig, Germany, July 6, 2023 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that the Company has received authorization for its custom-made bone and pectus excavatum scaffolds in Europe under EU medical devices regulations
By AKAMPION · Via GlobeNewswire · July 6, 2023
Cellbox Solutions GmbH Awarded €2.5 Million Grant Combined with an Equity Component of up to €10 Million Under the European Innovation Council´s Accelerator Program
- Cellbox Solutions selected by the EIC following the second 2023 EIC Accelerator cut-off
By AKAMPION · Via GlobeNewswire · July 5, 2023
Oliver Healthcare Packaging Strengthens Supply Chain, Adds In-Region Film & Foil Production
-- Acquisition of EK-Pack latest investment to bolster commitment to customers throughout Europe.
By AKAMPION · Via GlobeNewswire · June 29, 2023
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
- First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally- Enrollment ongoing in Germany, Spain, the Netherlands, and the United Kingdom
By AKAMPION · Via GlobeNewswire · June 28, 2023
BellaSeno Demonstrates Superior Biomechanical Properties of its 3-D Printed, Resorbable Scaffolds for Bone Reconstruction
Leipzig, Germany, June 20, 2023 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced comparative data on the biomechanical properties of different polycaprolactone/hydroxylapatite bone reconstruction scaffolds. The results, presented at the 24th EFORT Congress in Vienna, Austria, demonstrate that BellaSeno's established manufacturing process results in bone scaffolds that can withstand higher loads and longer stress cycles than those produced by competing technologies.
By AKAMPION · Via GlobeNewswire · June 20, 2023
Thermosome Announces Participation in IMAGIO Consortium to Improve Cancer Treatment
Munich, Germany – June 20, 2023 – Thermosome, a drug development company specializing in targeted tumor therapies, today announced its participation in the IMAGIO consortium set out to develop innovations in interventional oncology focused on lung cancer, liver cancer and soft tissue sarcomas (STS). The IMAGIO consortium, consisting of approximately 30 clinics, academic institutes, healthcare companies, and patient organizations, has been awarded a EUR 24 million grant from the Innovative Health Initiative, complemented by additional funding from industry partners to conduct research on less invasive cancer treatments.
By AKAMPION · Via GlobeNewswire · June 20, 2023
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
Zurich, May 30, 2023 –  MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for MP1032 for the treatment of Duchenne muscular dystrophy.
By AKAMPION · Via GlobeNewswire · May 30, 2023
selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
San Diego, CA, USA, and Munich, Germany – May 30, 2023 - selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments of T-cell mediated autoimmune diseases, today announced excellent initial safety results of the single ascending dose (SAD) stage in the Phase 1b trial of its drug candidate si-544 in atopic dermatitis patients. si-544 is a selectivity-optimized peptide blocking the ion channel Kv1.3.
By AKAMPION · Via GlobeNewswire · May 30, 2023
Thermosome Announces First Patient Dosed in Phase I Trial with Lead Program THE001
-    Addressing high unmet medical need in locally advanced soft tissue sarcoma-    Targeted tumor treatment independent of specific molecular targets or tumor subtypes
By AKAMPION · Via GlobeNewswire · May 24, 2023
ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
- First-in-class checkpoint inhibitor IOS-1002 (targeting LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and combination therapy in patients with advanced solid tumors
By AKAMPION · Via GlobeNewswire · May 24, 2023
Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer
ROTTERDAM, May 12, 2023 - Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announces the appointment of Dr. Rachel Abbott as Chief Executive Officer (CEO). Rachel steps up from her current role as Pan Cancer T’s Chief Scientific Officer (CSO), succeeding Katrien Reynders-Frederix who has served as CEO since the company’s inception.
By AKAMPION · Via GlobeNewswire · May 12, 2023
Positive Interim Data of BellaSeno's Clinical Trial with Resorbable Breast and Chest Implants Reported at RACS 2023
Leipzig, Germany, May 9, 2023 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced positive interim results from two clinical trials of its products sponsored by its Australian subsidiary, BellaSeno Pty. The results were presented at the 91st Annual Scientific Congress 2023 of the Royal Australasian College of Surgeons (RACS).
By AKAMPION · Via GlobeNewswire · May 9, 2023
Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6
- OMN6 demonstrates safety and tolerability at clinically significant dose levels  
By AKAMPION · Via GlobeNewswire · May 8, 2023
ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board
- Renowned immunology expert from MD Anderson Cancer Center to lead seasoned group of scientific advisors
By AKAMPION · Via GlobeNewswire · April 25, 2023
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
Berlin, Germany & Zurich, Switzerland – April 12, 2023 -- ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs' lead program for the treatment of cancer. ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
By AKAMPION · Via GlobeNewswire · April 12, 2023
EBViously Announces First Details of Its EBV-001 Vaccine Candidate for the Prevention of Epstein-Barr Virus (EBV)-Induced Diseases
Munich, Germany, April 3, 2023 – EBViously, a start-up developing novel vaccines based on next-generation virus-like particles, will present its approach and technology at the upcoming World Vaccine Congress 2023 (April 4-6, 2023) in Washington, DC (USA). The presentation will take place on Wednesday, April 5, 2023, at 2:55 p.m. EST in Room 201 of the Walter E. Washington Convention Center in Washington, DC.
By AKAMPION · Via GlobeNewswire · April 3, 2023
InfanDx AG Revises Strategy and Broadens Diagnostics Pipeline for Child Health
Cologne/Berlin, Germany, and Boston, MA, USA, March 28, 2023 – InfanDx AG, a privately held company focusing on the development and commercialization of novel diagnostic solutions for child health, today announced a strategic repositioning of the Company by broadening its pipeline of innovative solutions for child health.
By AKAMPION · Via GlobeNewswire · March 28, 2023
Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001
-   Novel compound for targeted tumor therapy to be evaluated in patients with soft tissue sarcoma-   First patients to be enrolled in Q2, 2023
By AKAMPION · Via GlobeNewswire · March 28, 2023
HpVac reports positive effects of its lead compound HpVac-R13 in a murine model of allergic asthma following oral administration
- Study results indicate beneficial effects on airway hyperresponsiveness, remodeling and inflammation
By AKAMPION · Via GlobeNewswire · March 27, 2023
Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer
- Leading translational medicine and neuroscience expert to head Dopavision’s research activities
By AKAMPION · Via GlobeNewswire · March 21, 2023
Cellbox Solutions Raises EUR 6.5 Million in Series A1 Financing Round
- CK Ventures, Fraunhofer Ventures, NRW.Venture and Fil Bros join forces with renowned private investors- Planned expansion of US business and launch of tailored cell therapy shipment solutions
By AKAMPION · Via GlobeNewswire · March 7, 2023
Evonik and BellaSeno advance commercialization of 3D-printed, bioresorbable implants
Essen and Leipzig, Germany, March 6, 2023. Evonik and BellaSeno, a developer of 3D-printed absorbable scaffolds, are working together to commercialize innovative 3D-printed scaffolds for bone regeneration. The bone scaffolds are made with Evonik’s Resomer® polymers and are used for large and complex bone defects. Both companies initially began collaborating in 2019 on scaffolds for chest wall and breast reconstruction. 
By AKAMPION · Via GlobeNewswire · March 6, 2023
Pan Cancer T Appoints Prof. Dr. Chiara Bonini to its Scientific Advisory Board
- Leading European T cell therapy researcher adds further scientific expertise
By AKAMPION · Via GlobeNewswire · February 23, 2023
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor
- Claus Andersson, PhD, joins Rewind´s Board of Directors
By AKAMPION · Via GlobeNewswire · January 25, 2023
Pan Cancer T Appoints Dr. Rachel Abbott as Chief Scientific Officer
- Strengthening of T cell research expertise to develop next-generation T cell therapies for patients with limited or no treatment options
By AKAMPION · Via GlobeNewswire · January 17, 2023
ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002
- Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023
By AKAMPION · Via GlobeNewswire · January 17, 2023
1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors
- Initiation of Phase 1/2 Clinical Trial Expected in Q1 2023
By AKAMPION · Via GlobeNewswire · December 13, 2022
Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team
- Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and development expertise
By AKAMPION · Via GlobeNewswire · November 29, 2022
HpVac Appoints Joana Vitte, MD, PhD, as Chief Scientific Officer
- Significant expansion of allergy research expertise
By AKAMPION · Via GlobeNewswire · November 23, 2022
Dopavision Appoints Dr. Dirk Sauer as Chair of the Company's Advisory Board
- Former Head of Novartis' Ophthalmology Development Unit to provide significant product development expertise and industry network
By AKAMPION · Via GlobeNewswire · November 16, 2022